It's time for an update on the Medical company Grifols, S.A. (NASDAQ:GRFS). It's been about 4 months since I last updated on the business, with that update being specific to an event where ...

The family that owns Spanish drugmaker Grifols and private equity firm Brookfield are considering whether to take the company private in a deal that could be worth around €5.5 billion (almost $6 ...

GRIFOLS transfer bags are used for sterile preservation and administration of blood components. Blood components can be obtained, stored and preserved without contact with the environment ensuring ...

Grifols announced on Thursday that it has signed a strategic agreement with Swiss laboratory automation firm Inpeco to provide automated instrumentation, robotics, and software to transfusion medicine ...

Grifols SA engages in the production of plasma ... The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked ...

Through a pioneering initiative called Chronos-PD, Grifols is partnering with the Michael J. Fox Foundation for Parkinson’s ...

Immunoglobulin therapy improves mobility in phase 2/3 study Grifols has announced positive results from its phase 2/3 clinical trial evaluating the efficacy and safety of intravenous immunoglobulin ...

Grifols, S.A. (NASDAQ:GRFS) delivered strong financial results in Q3 2024, showing solid growth and improved financial health. Revenue reached EUR 1,793 million, reflecting a 12.4% year-over-year ...

Grifols (GRFS) issued a statement to address certain information published in a media outlet on March 8, specifically a front-page article titled “The CNMV reveals to the judge ‘continuous ...

This page features the latest news about the Grifols Pref stock. Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton ...